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This study describes the effects of the introduction of universal infant pneumococcal conju-
gate vaccination in 2006 on invasive pneumococcal disease (IPD) among children and adults
in Germany with a focus on the dynamics of serotype distribution in vaccinated and non-
vaccinated age groups. Over a period of 22 years (1992–2014), microbiological diagnostic
laboratories from all over Germany have been sending isolates of IPD cases to the German
National Reference Center for Streptococci on a voluntary basis. Streptococcus pneumoniae
isolates were serotyped using Neufeld’s Quellung method. Among children <16 years, the
proportion of PCV7 serotypes among isolates from IPD cases decreased from 61.8% before
vaccination (1997–2006) to 23.5% in the early vaccination period (2007–2010; p = 1.30E-72)
and sank further to 5.2% in the late vaccination period (2010–2014; p = 4.59E-25). Similar
reductions were seen for the separate age groups <2 years, 2-4 years and 5-15 years.
Among adults, the proportion of PCV7 serotypes decreased from 43.4% in the pre-vaccina-
tion period (1992–2006) to 24.7% (p = 3.78E-88) in the early vaccination period and 8.2% (p
= 5.97E-161) in the late vaccination period. Both among children and among adults, the non-
PCV7 serotypes 1, 3, 7F and 19A significantly increased in the early vaccination period. After
the switch from PCV7 to PVC10/PCV13 for infant vaccination in 2010, serotypes 1, 6A and
7F significantly decreased. A decrease in serotype 19A was only observed in 2013–2014, as
compared to 2010–2011 (children p = 4.16E-04, adults p = 6.98E-06). Among adults, sero-
type 3, which strongly increased in the early vaccination period (p = 4.44E-15), remained at a
constant proportion in the late vaccination period. The proportion of non-PCV13 vaccine sero-
types increased over the whole vaccination period, with serotypes 10A, 12F, 23B, 24F and 38
most significantly increasing among children and serotypes 6C, 12F, 15A, 22F and 23B
increasing among adults. Eight years of childhood pneumococcal conjugate vaccination have
had a strong effect on the pneumococcal population in Germany, both among the target
group for vaccination as well as among older children and adults.
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Introduction
Streptococcus pneumoniae (pneumococcus) is a major cause of infectious disease worldwide.
Globally, over a million children and half a million adults die every year as a result of invasive
pneumococcal disease (IPD), including meningitis, sepsis and bacteremic pneumonia [1].
Non-invasive conditions like non-bacteremic pneumonia and otitis media further increase the
global burden of disease. Apart from being a pathogen, pneumococci are asymptomatically car-
ried in the nasopharynx, by up to 50% of children under the age of 2 years, and also by 2–5% of
adults [2, 3]. It is commonly assumed that colonization precedes disease, and that transmission
occurs from child to child and from children to (older) adults. However, circulation of pneu-
mococci among adults or transmission from adults to children is also possible [4]. The main
burden of invasive and non-invasive pneumococcal disease lies in young children (0–5 years of
age) and older adults (>50 years of age).
The introduction of vaccination aims to reduce the burden of pneumococcal disease, and
the currently available vaccines are all directed against the pneumococcal capsular polysaccha-
rides. The polysaccharide capsule is the primary virulence factor of Streptococcus pneumoniae
and currently over 93 different capsular types (serotypes) have been described [5].
The 23-valent pneumococcal polysaccharide vaccine (Merck, Pneumovax 23, PPV23) con-
tains polysaccharides of serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F,
18C, 19F, 19A, 20, 22F, 23F, and 33F. This vaccine is licenced for ages 2 years and older, there-
fore, it cannot be used to reduce the burden of pneumococcal disease in young children. In the
year 2000, a 7-valent pneumococcal conjugate vaccine was launched (Wyeth/Pfizer, Prevenar/
Prevnar, PCV7) containing serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. PCV7 consists of capsular
polysaccharides which are conjugated to a carrier protein (CRM197). In 2009, two higher-valent
pneumococcal conjugate vaccines were introduced: a 10-valent vaccine (GSK, Synflorix, PCV10),
which includes the PCV7 serotypes plus serotypes 1, 5 and 7F, and a 13-valent vaccine (Wyeth/
Pfizer, Prevenar13, PCV13), which includes the PCV10 serotypes plus serotypes 3, 6A and 19A.
PCV13 uses the same carrier protein as PCV7 (CRM197) whereas Synflorix usesHaemophilus
influenzae protein D as a carrier protein for 8 serotypes, tetanus toxoid for serotype 18C and
diphtheria toxoid for serotype 19F. PCVs elicit a protein immune response and result in immu-
nological memory, even in young children. Apart from systemic immunity against pneumococcal
disease, PCVs also induce mucosal immunity, which prevents carriage of the included serotypes.
Many countries have implemented pneumococcal vaccination programs for infants and
older adults. Whereas vaccination programs for adults (with PPV23) have resulted in relatively
low vaccination rates [6], vaccination programs for conjugate childhood vaccination have been
very successful [7, 8]: in vaccinated children, the programs have resulted in a marked reduction
of both IPD and carriage of serotypes included in the vaccine. Furthermore, they have resulted
in a reduction in vaccine-serotype IPD among older children and adults, a phenomenon called
herd protection [9]. Herd protection results from a reduced vaccine-serotype carriage among
vaccinated individuals who then have a lowered chance of transferring these serotypes to non-
vaccinated individuals.
Parallel to the reduction in serotypes included in the conjugate vaccines, an increase in IPD
caused by non-vaccine serotypes (replacement) was observed in many countries. However, in
most countries this increase was much lower than the decrease in vaccine serotype disease [10].
A recommendation for pneumococcal conjugate vaccination for all children under 2 years of
age was issued by the German standing committee on vaccination (STIKO) in July 2006 [11]. Ger-
many does not have a national immunization program, but vaccination costs of recommended
vaccinations are reimbursed by health insurance companies. PCV7 was licensed in Germany in
2001, followed by PCV10 in April 2009 and PCV13 in December 2009 (replacing PCV7).
Effects of PCV on Serotype Distribution in IPD in Germany
PLOS ONE | DOI:10.1371/journal.pone.0131494 July 1, 2015 2 / 17
horaria from Pfizer, Merck and SanofiPasteurMSD.
This study was in part funded by Pfizer Pharma
GmbH and Sanofi Pasteur MSD Germany. This does
not alter the authors' adherence to PLOS ONE
policies on sharing data and materials.
The actual choice of vaccine made by the parents/physicians is reflected in the prescription
data of different vaccine formulations for children under two years of age in Germany. Before
2009, only PCV7 was used. In 2009, 19.8% of prescriptions were PCV10, in 2010 this lowered
to 5.6%, in 2011 to 2.6% and in 2014 only 1.9% of prescriptions were PCV10 (data from IMS
Health, Germany, ‘Verordnungsindex Pharma (VIP)’).
For adults aged 60 years and older, the 23-valent polysaccharide vaccine (PPV23, SPMSD,
Pneumovax) has been recommended since 1998, currently as a single dose. A further vaccina-
tion recommendation exists for all children and adults with an increased risk for pneumococcal
disease due to underlying conditions. For children up to the age of four years, pneumococcal
conjugate vaccine is recommended; for individuals older than 5 years, a vaccination with
PCV13 or PPV23 is recommended [12].
The uptake of pneumococcal conjugate vaccine among children under two years of age in
Germany is 80–85% (as based on sold/prescribed doses) [13–16]. Among adults aged65
years PPV23 vaccination levels have been low in Germany (31%, [17]).
This study describes the effects of the introduction of childhood pneumococcal conjugate
vaccination on invasive pneumococcal disease among children and adults in Germany, focus-
ing on the dynamics of serotype distributions in vaccinated and non-vaccinated age groups
over a period of 22 years.
Materials and Methods
Study materials
The German National Reference Center for Streptococci (GNRCS) has conducted surveillance
for IPD in Germany since 1992, using a laboratory-based approach. IPD cases were defined as
Streptococcus pneumoniae isolates from blood, cerebrospinal fluid (CSF) or any other normally
sterile body fluid. Microbiological diagnostic laboratories from all over Germany have been
sending isolates of IPD cases to the GNRCS on a voluntary basis. In total, over 400 laboratories
have participated, including large, nationally-operating commercial labs. Participating labora-
tories are located in all German federal states, and the number of laboratories per federal state
correlates to the different population densities of the states. In the last 7 years of the study
(2007–2008 to 2013–2014), reported cases varied between 0.7 per 100,000 inhabitants per year
(Schleswig-Holstein) and 5.6 per 100,000 per year (Bremen) (Table in S1Table).
Over the years, the surveillance system has been improved. In 2001, surveillance for adults
was enhanced in North Rhine-Westphalia (22% of German population), as well as in Bavaria
and Saxony in 2006. On each occasion, all laboratories in the respective federal states were
approached and asked to send in isolates. In 2007, a web-based surveillance system called
PneumoWeb (www.rki.de/pneumoweb) was set up by the Robert Koch Institute in collabora-
tion with the GNRCS. PneumoWeb enables the laboratories to report a case of IPD via an
online system, and directly print the corresponding information as a Case Report Form to send
to the GNRCS, accompanied by the IPD isolate. The web-based system resulted in a large
increase in reported cases for adults, whereas the amount of cases for children remained at the
same high level. For children, using our capture-recapture incidence calculations, we deter-
mined that before the vaccination recommendation, 40–50% of all IPD cases had a sample sent
to the GNRCS. This percentage increased to 50–60% after vaccination introduction [18].
Characterization of isolates and serotyping
Species identification was performed using bile and optochin testing. In dubious cases, PCR
analysis of several genes was performed (ply, lytA, sodA, 16S-rRNA). As a last resort, MLST
was performed. Pneumococcal isolates were serotyped by Neufeld’s Quellung reaction using
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type and factor sera provided by the Statens Serum Institut, Copenhagen, Denmark. Isolates
were considered non-typeable when there was no reaction with any of the antisera.
Statistical methods
Cases were grouped per pneumococcal season (from July to June of consecutive years) because
of known infection clusters during winter. For the analysis of vaccination effects, we defined
three time periods. The pre-vaccination period from 1997–2006 summarizes 9 pneumococcal
seasons in which children were not vaccinated (for adults: 1992–2006, 14 seasons). The season
2006–2007 was considered a transition year in which pneumococcal conjugate vaccination was
introduced, and was taken out of the analysis. The early vaccination period summarized the
three seasons (2007–2008, 2008–2009 and 2009–2010) in which PCV7 was used, and the late
vaccination period summarizes four seasons (2010–2011, 2011–2012, 2012–2013 and 2013–
2014) in which higher-valent vaccines (mainly PCV13) were used. To study the most recent
effects of higher-valent vaccination, a direct comparison of the seasons 2010–2011 and 2013–
2014 was made.
Differences in proportions were tested by Fisher´s exact test with a two-sided p-value<0.05
considered statistically significant. Analyses were conducted using R (R Foundation for Statisti-
cal Computing, Vienna, Austria, 2014).
Ethical statement
An ethical approval was not required since the study was performed with Streptococcus pneu-
moniae isolates that resulted from routine microbiological diagnostic procedures as requested
by the treating physician. No additional biological specimens were taken for the purpose of this
study. Specimens were anonymized and only data on year and month of birth, sex, type of
specimen and hospital/laboratory where the case was diagnosed were registered.
Results
From July 1992 until June 2014, a total of 3,853 isolates from invasive pneumococcal disease
(IPD) among children (<16 years) and 20,382 isolates from IPD among adults (16 years)
were received at the GNRCS. Of all isolates (24,235), 15.9% were from children under 16 years
of age (11.7% from children under 5 years of age). 68.5% of the isolates were from adults over
50, 53.8% from adults over 60 years of age (Fig 1). The median age among isolates from chil-
dren was 1 year (21 months), and 57.3% of isolates were from male patients (40.0% female,
2.7% gender unknown). Among adults the median age was 67 years, and 45.3% of isolates were
from male patients (54.2% female, 0.5% gender unknown). All isolates from children were ser-
otyped, whereas 20,104 isolates from adults were available for serotyping (Fig 2).
Effects of PCV on IPD among children
In the pre-vaccination period, PCV7 serotypes represented an average of 61.8% of all isolates
among children. This proportion was reduced to 23.5% in the early vaccination period
(p = 1.30E-72) and sank further to 5.2% in the late vaccination period (p = 4.59E-25). The
reduction in the early vaccination period was highly significant for all PCV7 serotypes except
for serotype 18C (p = 0.21). Reductions between the early and late vaccination period were
much less significant, mainly due to the already very low numbers (Table 1). The reduction of
serotype 18C reached statistical significance in the late vaccination period (p = 4.36E-05). Simi-
lar reductions were seen for the separate age groups<2 years, 2–4 years and 5–15 years, though
reductions in the two higher age groups are less significant due to lower numbers (Tables A-D
Effects of PCV on Serotype Distribution in IPD in Germany
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in S1Text). Comparison of the season 2010–2011 with 2013–2014 shows that PCV7 serotypes
have almost disappeared in all age groups.
Of the six extra serotypes included in PCV13 as compared to PCV7, four showed an
increase in the early vaccination period: 1 (p = 1.24E-10), 3 (p = 3.86E-04), 7F (p = 3.82E-10)
and 19A (p = 2.05E-07). The proportion of serotype 6A increased, but not significantly,
Fig 1. Age distribution of reported IPD isolates (1992–2014) in Germany (n = 24,235). Left y-axis: number of reported cases, right y-axis cumulative
percentage of all cases. Data represent the age distribution of isolates sent to the GNRCS on a voluntary basis. Since the surveillance system was improved
several times (see materials and methods section), the graph does not necessarily represent the actual prevalence of IPD in the different age groups in
Germany.
doi:10.1371/journal.pone.0131494.g001
Fig 2. Numbers of reported IPD isolates among children (n = 3,853, all serotyped) and adults (n = 20,382, serotyped: n = 20,104) in Germany.
doi:10.1371/journal.pone.0131494.g002
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whereas the number of serotype 5 isolates was too low for analysis. In the late vaccination
period, a significant decrease was observed for serotypes 1, 6A and 7F. Serotypes 3 and 19A fur-
ther increased, but the increase was no longer statistically significant. The increase in serotypes
19A and 3 persisted well into the late vaccination period. A decrease in serotype 19A was only
observed in 2013–2014, as compared to 2010–2011 (p = 4.16E-04). However, when looking at
the separate age groups, the impact of the higher-valent vaccination becomes very clear among
children<2 years of age, with each of the six extra serotypes decreasing (Tables A-D in
S1Text).
The proportion of non-PCV13 vaccine serotypes among IPD in children in the pre-vaccina-
tion period was 15.6%. This proportion increased to 29.7% in the early vaccination period, and
to 59.2% in the late vaccination period. The most significantly increasing serotypes were 10A,
12F, 23B, 24F and 38. Table 1 lists only those non-PCV13 serotypes which showed statistically
significant changes. Table A in S1Text lists all non-PCV13 serotypes.
Effects of PCV on IPD among adults
PCV7 serotypes represented 43.4% of all isolates among adults in the pre-vaccination period
(1992–2006). This proportion decreased to 24.7% (p = 3.78E-88) in the early vaccination
period, and to 8.2% (p = 5.97E-161) in the late vaccination period. The reduction was highly
significant for all serotypes except for 19F (p = 0.095) in the early vaccination period, and
became highly significant for all serotypes in the late vaccination period (Table 2). Looking at
separate age groups (16–49 years, 50–60 years, 61–75 years and>75 years), similar reductions
were seen, with the lowest reductions for serotypes 18C and 19F (Tables E-I in S1Text).
Of the PCV13-non-PCV7 serotypes, 1, 3, 7F and 19A increased in the early vaccination
period, whereas 6A decreased, but only the increase in 7F reached statistical significance
(1.96E-02). In the late vaccination period, serotypes 1, 6A and 7F significantly decreased. Sero-
type 19A only showed a decrease (p = 6.98E-06) in 2013–2014 (as compared to 2010–2011).
Serotype 3, which strongly increased in the early vaccination period (p = 4.44E-15), remained
at a constant prevalence in the late vaccination period.
Non-PCV13 serotypes made up 27.7% of all isolates in the pre-vaccination period, increas-
ing to 33.4% in the early vaccination period, to 52.7% in the late vaccination period and to
63.7% in the last season (2013–2014). The most significantly increasing serotypes among adults
were 6C, 12F, 15A, 22F and 23B. Table 2 lists only those non-PCV13 serotypes which showed
statistically significant changes. Table B in S1Text lists all non-PCV13 serotypes.
Serotype 19A
Among children<2 years of age, cases with serotype 19A have increased in the early vaccina-
tion period (p = 3.03E-08). During the late vaccination period, 19A decreased as compared to
the early vaccination period, but not significantly (p = 9.07E-01). A significant decrease in 19A
cases was only observed when comparing 2010–2011 to 2013–2014 (p = 1.06E-03). Among
children 2–4 years of age, 19A cases increased significantly in both the early and the late vacci-
nation period, and a (non-significant) decrease was only seen in the last surveillance years
(2010–2011 vs. 2013–2014; p = 2.36E-01). Among older children (5–15 years of age), neither
the vaccination increase in 19A cases nor the decrease in the latter surveillance years reached
statistical significance (Tables A-D in S1Text). Among adults, the dynamics of serotype 19A
were similar: a significant increase in all age groups during both the early and the late vaccina-
tion periods. Only when comparing 2010–2011 to 2013–2014 a significant decrease in reported
cases with serotype 19A was observed for all age groups except for the 16–49 year olds, where
the decrease did not reach significance (p = 4.27E-01; Tables E-I in S1Text).
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Serotype 3
In the early vaccination period, reported cases with serotype 3 significantly increased in all age
groups, except for children 5–15 years of age, among whom a non-significant decrease was
observed (p = 8.36E-01). In the late vaccination period, and also when comparing 2010–2011
to 2013–2014, no significant changes in serotype 3 levels were observed in any age group
(Tables A-I in S1Text).
Serotype 1
The number of reported cases with serotype 1 increased in the early vaccination period in each
separate age group, reaching statistical significance among children 0–1 years and 2–4 years,
and among adults 16–49 years and 50–60 years. In the late vaccination period, a steep decrease
in the number of reported serotype 1 cases was observed among all age groups, most signifi-
cantly among 16–49 year olds (p = 2.51E-07) and>75 year olds (p = 9.42E-07) (Tables A-I in
S1Text).
PPV23 serotypes among adults
In the pre-vaccination period, PPV23 serotypes were responsible for 87.4% of all IPD cases
reported from adults (Table 2) with little variation in this percentage over the 14 prevaccina-
tion seasons (84.2%- 90.6%). In the early vaccination period, this percentage decreased signifi-
cantly to 84.1% (p = 3.38E-06), due to the significant decrease in PCV7 serotypes (p = 3.78E-
88). The decrease became more significant in the late vaccination period (76.5%, p = 5.00E-29),
caused by the continuing decrease in PCV7 serotypes (p = 5.97E-161) and the decrease in
PCV13-non-PCV7 serotypes (p = 8.68E-04). Several of the serotypes included in PPV23 but
not in PCV13 significantly increased, either over the whole vaccination period (22F, 33F), or
only in the late vaccination period (8, 12F).
Serotypes never detected
We have not detected any of the following 28 serotypes in IPD cases among children in Ger-
many: 6D, 7B, 7C, 10C, 11C, 11D, 11E, 11F, 16A, 17A, 22A, 25A, 25F, 32A, 32F, 33C, 33D, 40,
41A, 41F, 42, 43, 44, 45, 46, 47A, 47F, 48. Of these 28 serotypes, the following 17 serotypes
have not been found among adult IPD cases either: 10C, 11D, 11E, 16A, 32A, 32F, 33C, 33D,
40, 41A, 41F, 42, 43, 44, 46, 47A, 47F.
Serotypes in transition season 2006–2007
Two serotypes were found only once and only in the transition season 2006–2007. This con-
cerned a case of serotype 10F in a child and a case of the new serotype 6G (see below) in an
adult.
New serotypes
In the course of this study, two new serogroup 6 serotypes (6F and 6G) were discovered, which
have been described by Melissa Oliver and our group: [19].
Dynamics of serotype distribution over time
The development over time of the serotype distribution for seven different age groups is pre-
sented in Fig 3. Immediately after the start of PCV7 vaccination, a steep drop in reported cases
with PCV7 serotypes was observed for children<2 years of age, resulting in almost no reported
Effects of PCV on Serotype Distribution in IPD in Germany
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PCV7 cases in 2013–2014. Among 2–4 year olds, a similar decrease was observed, although it
was slower. Among children aged 5–15 years, a decrease in PCV7 serotypes was only observed
starting in 2010–2011. In all three age groups, the PCV13-non-PCV7 serotypes increased in
the early vaccination period, but decreased in the late vaccination period. Non-PCV13 sero-
types increased among all three childhood age groups, but to a lesser extent among older chil-
dren (5–16 years of age). The increase in non-PCV13 serotypes was most pronounced for
children<2 years and from 2011–2014. The total amount of reported IPD cases has decreased
in all childhood age groups in the vaccination period.
Among adults, a reduction of PCV7 serotypes was observed in all four age groups starting
from 2008–2009. PCV13-non-PCV7 serotypes increased considerably in all age groups in the
early vaccination period, and decreased again in the late vaccination period. The decrease was
much less pronounced among older adults (>75 years of age). Cases with non-PCV13 sero-
types have increased in all four adult age groups and during the whole vaccination period
(2007–2014). A reduction in the total amount of reported IPD cases was not observed in any of
the four adult age groups (2007–2014).
Fig 4A shows the dynamics of the individual serotypes among children over the surveillance
period (1997–2014). In the early vaccination period, PCV7 serotypes (blue) decreased, whereas
PCV13-non-PCV7 serotypes (green and orange), as well as non-PCV13 serotypes (black, grey
and purple), increased. In the late vaccination period, PCV13-non-PCV7 serotypes decreased,
while the non-PCV13 serotypes continued to increase. The amount of reported cases per
Fig 3. Isolates from IPD cases in Germany from 1997/1998 to 2013/2014 according to age groups and PCV7 vaccine-type (red), PCV13-non-PCV7
vaccine-type (blue) or non-PCV13 vaccine-type (green). The total number of IPD cases is shown in black.
doi:10.1371/journal.pone.0131494.g003
Effects of PCV on Serotype Distribution in IPD in Germany
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season has clearly decreased from 2006–2007 to 2013–2014. In Fig 4B, the dynamics of the
serotype distribution in the vaccination period (2007–2014) among adults is presented. Here,
PCV7 serotypes lost importance as well, while PCV13-non-PCV7 serotypes increased in the
early vaccination period and decreased in the late vaccination period. Non-PCV13 serotypes
continuously increased over the whole vaccination period (2007–2014). A reduction in the
number of reported cases per pneumococcal season is not observed.
Discussion
Our study has several limitations. Since IPD is not a notifiable disease in Germany, isolates
were sent in by clinical microbiological laboratories on a voluntary basis, which bears the risk
of under-reporting. Furthermore, the systematic sampling of invasive isolates from adults
(1992) and children (1997) was taken up at different times, and for adults, the surveillance
included population-based studies in three German federal states: North Rhine-Westphalia,
started in 2001; Bavaria, started in 2006; Saxony, started in 2006. Over the years, the surveil-
lance project has been continuously intensified, particularly after the recommendation for uni-
versal infant vaccination against pneumococci was issued. This recommendation unavoidably
led to an increased awareness of IPD among clinical microbiologists and pediatricians. Finally,
in 2007, the introduction of PneumoWeb, a web-based reporting system contributed to an
increased number of reported cases of IPD among adults, from 200–500 cases per season to
over 2000 cases per season. The introduction of PneumoWeb did not lead to increased report-
ing among children, reflecting the good level of reporting already reached in previous years.
The impact of pneumococcal conjugate vaccination on IPD caused by PCV7 serotypes has
been vast, with PCV7 serotypes having almost disappeared among children<2 years of age.
Similarly, PCV7 serotypes have been strongly reduced among older children and adults, indi-
cating herd protection. These effects are in accordance with reductions of IPD incidence
among children published by our group [20] and with reports from other countries that have
introduced pneumococcal conjugate vaccination [21]. Among the PCV13-non-PCV7 sero-
types, serotypes 1, 3, 7F and 19A increased in the early vaccination period (in all age groups),
when PCV7 was used. These serotypes apparently occupied the niche vacated by the PCV7
Fig 4. Serotype distribution of IPD cases among children (1997–2014, A) and adults (2007–2014, B) in Germany. Blue: PCV7 serotypes, Green:
PCV10-PCV7 serotypes, Orange: PCV13-PCV10 serotypes, Black/Gray: major non-PCV13 serotypes, Purple: other non-PCV13 serotypes.
doi:10.1371/journal.pone.0131494.g004
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serotypes. This replacement was observed in other countries as well [10]. After the introduction
of higher-valent vaccination, serotypes 1, 7F and 6A decreased in all age groups. This immedi-
ate effect of higher-valent vaccination was also observed in other countries [22–25]. The steep
rise in serotype 19A cases, which occurred in the early vaccination period, was only reverted in
2013–2014. Effects on serotype 19A have been more direct in other countries [26]. An explana-
tion for the delayed effect in Germany could be the late onset of the increase in 19A after the
start of PCV7 vaccination [27]. Therefore, when higher-valent vaccines were introduced, 19A
was still steeply increasing, and it took time for this increase to first diminish and then be
reversed. Obviously, the decrease in non-targeted age groups appeared with even more delay.
A decrease of serotype 3 cases was observed among children<2 years of age, in the late vac-
cination period, but it did not reach significance. Case numbers of serotype 3 among children
are very low, and therefore it is difficult to judge whether there is a vaccination effect. However,
serotype 3 cases did not increase, which might have been expected if the vaccine had no effect
on serotype 3 at all. Interestingly, a herd protection effect towards the older age groups was not
observed either. Among adults, serotype 3 has increased strongly and is now the most prevalent
serotype. Steens et al. report very low numbers of serotype 3 cases among children<2 years in
Norway, and also did not observe an effect of PCV13 on serotype 3 in non-targeted age groups
[24]. Harboe et al. report no change in serotype 3 following PCV13 vaccination in Denmark
[25]. Miller et al. report a non-significant reduction of serotype 3 since PCV13 introduction,
whereas Kaplan et al. report a 68% decrease in serotype 3 among patients from eight US chil-
dren’s hospitals, although numbers were low [28].
The significant increase of non-PCV serotypes shows that replacement is an issue after each
PCV introduction, even though the net effect of vaccination remains positive. Several of the
upcoming serotypes in this study (6C, 10A, 12F, 15A, 22F, 23B, 24F and 38), have been
described in other studies as well [24, 25]. The most strongly increasing serotypes, 23B and
15A, were also found to be increasing in Norway [24] and in Hong Kong [29], respectively.
The immediate, strong and lasting decrease in serotype 1 cases in all age groups in the late
vaccination period is enigmatic. For other serotypes, the herd protection effects among non-
targeted age-groups came with a delay in time of about one year. For serotype 1, the observed
reduction was as fast as in the directly-vaccinated age groups. A reduction in serotype 1 was
not observed among adults in Denmark [25] but it was seen in Norway, and appears to have
occurred just as fast [24].
In the early vaccination period, an immediate decrease of the PCV7 serotypes was observed
among children<2 years of age. Among 2–4 year old children, an immediate decrease was also
seen, but it was slower. Among older children (5–15 years), and among adults, the decrease
came with a considerable delay (2010–2011 and 2008–2009, respectively). This shows that
herd protection often comes into effect with a time delay. For the PCV13-non-PCV7 serotypes,
an increase in the early vaccination period, followed by a decrease in the late vaccination period
was observed in all age groups. Again, the decrease occurred with a delay in the non-vaccinated
age groups. Interestingly, the decrease was less strong among the oldest adults (>75 years).
The share of PPV23 serotypes among adult IPD cases remained the same over the entire
prevaccination period, indicating little effect of PPV23 vaccination. This could either be due to
limited effectiveness of the PPV23 vaccine, or to low levels of vaccination among adults in Ger-
many (31%, [17]). The PPV23 serotype share changed slightly in the early vaccination period
as compared to pre-vaccination times. This was due to the fact that all of the replacement sero-
types (1, 3, 7F, 19A) were included in PPV23. In the late vaccination period, the share of
PPV23 serotypes decreased sharply, as now only some of the replacement serotypes were
included in PPV23 (8, 12F, 22F, 33F), whereas others were not (6C, 15A, 23B).
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It is of interest that a total of 17 serotypes have never been detected during our 22 years of
surveillance. Obviously, serotype 11E cannot be distinguished from 11A using antisera and
therefore was not detected in our study [30]. The remaining 16 serotypes, however, are so rare
that they are hardly ever (if at all) reported in any surveillance studies. The current epidemio-
logical relevance of these serotypes therefore remains unclear.
In the course of this study, two new serotypes (6F and 6G) were detected [19]. Both isolates
show point mutations in the capsular genes, resulting in new variants of the capsular polysac-
charide. Whether these serotypes arose as a consequence of vaccination pressure remains
unclear, since one of the variants already appeared in 2006, i.e. before the start of vaccination
in Germany.
Conclusions
Eight years of childhood pneumococcal conjugate vaccination have had a strong effect on the
pneumococcal population in Germany, both among vaccinated children as well as among non-
vaccinated children and adults. Serotypes included in the vaccines have strongly diminished,
but have not disappeared completely. Non-vaccine serotypes have gained importance, with
several single serotypes occurring much more frequently than others. These phenomena stress
the importance of continued surveillance in order to monitor the dynamics of the pneumococ-
cal population under vaccination pressure and inform the development of higher-valent pneu-
mococcal vaccines.
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